|[January 11, 2013]
Research and Markets: Influvac (Seasonal Influenza Vaccine) Forecast and Market Analysis 2012-2022
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/rfgzg5/influvac)
has announced the addition of GlobalData's new report "Influvac
(Seasonal Influenza Vaccine) Forecast and Market Analysis" to their
Influvac (Seasonal Influenza Vaccine) Forecast and Market Analysis.
Seasonal Influenza is a respiratory infection caused by influenza virus
that results in mild to severe symptoms, such as fever, cold and cough.
The market is heavily driven by the sales of prophylactic vaccine
treatments to prevent infection. Currently, trivalent intramuscular
vaccines such as Sanofi's Fluzone and Vaxigrip, GlaxoSmithKline's
Fluarix and FluLaval and Novartis' Fluvirin garner the majority stake of
the market. However, with the entrance of vaccines with novel routes of
administration, such as AstraZeneca's intranasal FluMist and Sanofi's
Fluzone IntraDeral, GlobalData projects a dramatic shift favoring the
adoption of such vaccines over the traditional intramuscular vaccines.
GlobalData also anticipates that manufacturers that launch quadrivalent
formulations will steal market share, patient share, and revenue from
the trivalent influenza vaccines currently available.
Influvac is a trivalent, inactivated sub-unit vaccine designed to
immunize recipients against seasonal influenza infection. The viral
subtypes used in Influvac are propagated in chicken eggs, inactivated,
and purified by centrifugation. Influvac is marketed by Abbott, as part
of its acquisition of Solvay Pharmaceuticals in 2010. Influvac is
expected to lose market share throughout Europe, as we expect
quadrivalent influenza vaccines to dominate the European market by 2022.
Reasons to buy
- Understand and capitalize by identifying products that are most likely
to ensure a robust return
- Stay ahead of the competition by understanding the changing
competitive landscape for seasonal influenza
- Effectively plan your M&A and partnership strategies by identifying
drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth
analysis of Influvac performance
- Obtain sales forecast for Influvac from 2012 to 2022 in France,
Germany, Italy, Spain and China.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
For more information visit http://www.researchandmarkets.com/research/rfgzg5/influvac
Source (News - Alert): GlobalData
[ InfoTech Spotlight's Homepage ]